ライフサイエンスコーパス: Haemophilus influenzae type b

1 from ALRI, after pneumococcal pneumonia and Haemophilus influenzae type b.

2 and, when applicable, use of vaccine against Haemophilus influenzae type b.

3 ollicular, and secondary humoral response to Haemophilus influenzae Type b.

4 e cleavage of the capsular polysaccharide of Haemophilus influenzae type b.

5 pathogens were Streptococcus pneumoniae and Haemophilus influenzae (type B and non-type B).

6 become the predominant invasive pathogen as Haemophilus influenzae type b and pneumococcal vaccine u

7 ca, the widespread use of vaccines targeting Haemophilus influenzae type b and Streptococcus pneumoni

8 and of occult bacteremia since the advent of Haemophilus influenzae type b and Streptococcus pneumoni

9 , and whole-cell pertussis; hepatitis B; and Haemophilus influenzae type b) and pneumococcal vaccine.

10 ent vaccine (diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and hepatitis B) at 6, 10

11 include pneumococcus, group B Streptococcus, Haemophilus influenzae type b, and meningococcus vaccine

12 iphtheria and tetanus toxoids and pertussis; Haemophilus influenzae type b; and hepatitis B), based o

13 hybridized with DNA probes specific for the Haemophilus influenzae type b cap export region was clon

14 er the human antibody (Ab) repertoire to the Haemophilus influenzae type b capsular polysaccharide (H

15 We compared the antibody response to Haemophilus influenzae type b capsular polysaccharide (P

16 A Haemophilus influenzae type-b capsular polysaccharide-CR

17 -tetanus-acellular pertussis-inactived polio-Haemophilus influenzae type b combined vaccine (DTaP-IPV

18 C, W, Y polysaccharide vaccine (PsACWY); or Haemophilus influenzae type b conjugate vaccine (Hib-TT)

19 To assess whether combining a Haemophilus influenzae type b conjugate vaccine (PRP-T)

20 Literature on hepatitis B, rotavirus, Haemophilus influenzae type b conjugate, and pneumococca

21 phtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b (DTaP-Hib) conjugate vacci

22 t diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib) administere

23 s-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTaP-IPV-Hib) vaccine sin

24 nfants received diphtheria-tetanus-pertussis/Haemophilus influenzae type b (DTP/Hib; group 1), DTP/Hi

25 clinical significance and characteristics of Haemophilus influenzae type b genogroup strains isolated

26 Now that invasive disease caused by Haemophilus influenzae type b has been largely controlle

27 A conjugate vaccine containing Haemophilus influenzae type b (Hib) and group C meningoc

28 DN T-cell populations which proliferated to Haemophilus influenzae type b (Hib) antigen.

29 treptococcus pneumoniae (S. pneumoniae), and Haemophilus influenzae type b (Hib) are three most commo

30 Diseases of early childhood associated with Haemophilus influenzae type b (Hib) can now be prevented

31 Haemophilus influenzae type b (Hib) capsular polysacchar

32 ficance of reduced antibody responses to the Haemophilus influenzae type b (Hib) component of acellul

33 ed (DTaP), inactivated poliovirus (IPV), and Haemophilus influenzae type b (Hib) conjugate vaccine (D

34 e United States in the early 1990s, when the Haemophilus influenzae type b (Hib) conjugate vaccine fo

35 Haemophilus influenzae type b (Hib) conjugate vaccine is

36 In October 1992, Haemophilus influenzae type b (Hib) conjugate vaccine wa

37 Haemophilus influenzae type b (Hib) conjugate vaccine, d

38 rat model to evaluate the immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines a

39 The widespread use of Haemophilus influenzae type b (Hib) conjugate vaccines h

40 The development of Haemophilus influenzae type b (Hib) conjugate vaccines h

41 sting of the capsular polysaccharide (PS) of Haemophilus influenzae type b (Hib) covalently linked to

42 ives experienced very high rates of invasive Haemophilus influenzae type b (Hib) disease and carriage

43 ations have a 10-fold increased incidence of Haemophilus influenzae type b (Hib) disease compared wit

44 The incidence of invasive Haemophilus influenzae type b (Hib) disease has signific

45 Since 1999, the number of cases of Haemophilus influenzae type b (Hib) disease in the UK ha

46 LISA was adapted for the measurement of anti-Haemophilus influenzae type b (Hib) IgG avidity.

47 Haemophilus influenzae type b (Hib) invasive disease and

48 Haemophilus influenzae type b (Hib) is a leading cause o

49 arly with Neisseria meningitidis group C and Haemophilus influenzae type b (Hib) oligosaccharide-CRM1

50 Haemophilus influenzae type b (Hib) organisms produce pi

51 during the third trimester of pregnancy with Haemophilus influenzae type b (Hib) polyribosylribitol p

52 Antibody avidity to Haemophilus influenzae type b (Hib) polysaccharide (PS)

53 Previous studies in children have shown that Haemophilus influenzae type b (Hib) polysaccharide conju

54 luated the effect of donor immunization with Haemophilus influenzae type b (HIB) polysaccharide-conju

55 he serum Ab of young children immunized with Haemophilus influenzae type b (Hib) PS conjugate vaccine

56 Two isogenic mutants of Haemophilus influenzae type b (Hib) strain A2 were prepa

57 ng hospital in Malawi during introduction of Haemophilus influenzae type b (Hib) vaccination and the

58 The introduction of Haemophilus influenzae type b (Hib) vaccination of child

59 The schedule for Haemophilus influenzae type b (Hib) vaccination of infan

60 rst country in Africa to introduce conjugate Haemophilus influenzae type b (Hib) vaccine, which, as i

61 Streptococcus pneumoniae polysaccharide and Haemophilus influenzae type b (Hib) vaccines in ITP pati

62 with pneumococcal, tetanus toxoid (TT), and Haemophilus influenzae type B (HIB) vaccines.

63 Protection against Haemophilus influenzae type b (Hib), a rapidly invading

64 uding congenital rubella syndrome), invasive Haemophilus influenzae type b (Hib), acute hepatitis B,

65 y controls were immunized with pneumococcal, Haemophilus influenzae type b (Hib), and meningococcal v

66 ribitol (PRP) polysaccharides extracted from Haemophilus influenzae type b (Hib), and the correspondi

67 s, Neisseria meningitidis group C (MenC) and Haemophilus influenzae type B (Hib), both of which are c

68 mation induced by lipooligosaccharide (LOS), Haemophilus influenzae type b (Hib), or Listeria monocyt

69 ride conjugate vaccines that protect against Haemophilus influenzae type b (Hib), serogroup C Neisser

70 isease caused by the gram-negative bacterium Haemophilus influenzae type b (Hib).

71 Haemophilus influenzae type b is a common cause of invas

72 Haemophilus influenzae type b is an encapsulated bacteri

73 Haemophilus influenzae type b is an important cause of m

74 ion of heme-hemopexin as a source of heme by Haemophilus influenzae type b is dependent on expression

75 cine priming, before a booster of a combined Haemophilus influenzae type b-MenC conjugate vaccine and

76 against some types of bacterial meningitis (Haemophilus influenzae type b, Neisseria meningitidis gr

77 , 1.9 for childhood vaccination, and 2.6 for Haemophilus influenzae type b (P<.01 for each).

78 to characterise disease syndromes caused by Haemophilus influenzae type b, pneumococcus, rotavirus,

79 ent predominate in the human response to the Haemophilus influenzae type b polysaccharide (Hib PS).

80 factors, but differed from that of 43 Abs to Haemophilus influenzae type b polysaccharide, a prototyp

81 Five genetic islands (HiGI) found in Haemophilus influenzae type b strain Eagan were used as

82 intranasally colonized with pairs of marked Haemophilus influenzae type b strains, we demonstrate th

83 duction of vaccines against pneumococcus and Haemophilus influenzae type b (the most important causes

84 Initial binding of Haemophilus influenzae type b to the human nasopharynx i

85 osynthesis of lipid A) have been cloned from Haemophilus influenzae type b using a hybridisation-base

86 oxoids and to meningococcal, salmonella, and Haemophilus influenzae type b vaccinations.

87 a, tetanus, pertussis, measles, rubella, and Haemophilus influenzae type b vaccine antigens were comp

88 e, hepatitis B vaccine, and in some children Haemophilus influenzae type b vaccine).

89 s-acellular pertussis-inactivated poliovirus/Haemophilus influenzae type b vaccine; age 6/10/ 14 week

90 that pediatric providers conserve available Haemophilus influenzae type B vaccines by delaying the a

91 Because of a notable recall of Haemophilus influenzae type B vaccines by Merck & Co Inc

92 r pertussis, inactivated polio, hepatitis B, Haemophilus influenzae type b vaccines); (2) 4CMenB at 2

93 ng countries in 2015, using pneumococcal and Haemophilus influenzae type b vaccines.

94 the introduction of the conjugate vaccines, Haemophilus influenzae type b was the major cause of bac

95 sphate (PRP), the capsular polysaccharide of Haemophilus influenzae type b, was predominantly monomer

96 reactive with the capsular polysaccharide of Haemophilus influenzae type b, was purified and its chem

97 g with the first such described protein from Haemophilus influenzae type B, we termed the H. ducreyi

98 olysaccharide-protein conjugate vaccines for Haemophilus influenzae type b, which have proven to be e

99 We addressed these questions with Haemophilus influenzae type b, which metabolizes relativ

100 , tetanus, pertussis, hepatitis B virus, and Haemophilus influenzae type b), yellow fever, measles, a